Boan Biotech

About Boan Biotech

Boan Biotech, established in 2013, operates as a fully-integrated biopharmaceutical company engaged in the development, manufacturing, and commercialization of biologics. The firm was acquired by Luye Pharma Group in 2019, which accelerated its strategic development in the biopharmaceutical field. A significant milestone was achieved on December 30, 2022, when the company was officially listed on the Main Board of the Hong Kong Stock Exchange, raising approximately HK$152.8 million in its initial public offering.

The company is led by Jiang Hua, who serves as Chairlady and Chief Executive Officer. Her career began at Luye Group in 1998, where her role evolved from international trade to managing company strategy, mergers, and acquisitions, aligning with the founder's vision of globalizing China's innovative drugs. This extensive experience in multinational management and strategic investments within the pharmaceutical industry has been instrumental in shaping Boan Biotech's trajectory.

Boan Biotech employs a risk-balanced business model, commercializing biosimilars to generate immediate cash flow that funds the development of a pipeline of new drugs. The company focuses on key therapeutic areas including oncology, autoimmune diseases, ophthalmology, and metabolic diseases, serving hospitals and institutions primarily in Mainland China, while also developing products for markets in the U.S. and the European Union. Revenue is generated through the sale of its pharmaceutical products. For the fiscal year 2024, the company reported total revenue of RMB 726.3 million and achieved its first annual net profit of RMB 73.19 million.

The company's product portfolio includes both commercialized biosimilars and innovative antibody drug candidates. As of early 2025, three products are on the market: Boyounuo®, a bevacizumab biosimilar for treating various cancers; Boyoubei®, a denosumab biosimilar for osteoporosis; and Boluojia®, another denosumab biosimilar for treating giant cell tumors of bone. These products have reached approximately 3,000 hospitals and institutions across China. Boan's research and development efforts are supported by several technology platforms, including a Human Antibody Transgenic Mouse and Phage Display Technology Platform, a Bispecific T-cell Engager Technology Platform, and an ADC (Antibody-Drug Conjugate) Technology Platform. This integrated R&D and manufacturing capability enables the company to independently develop its products from discovery through to commercial production.